Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 377, Issue 8, Pages 756-768Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMra1610570
Keywords
-
Categories
Funding
- AbbVie
- Bristol-Myers Squibb
- Idenix
- Gilead
- GlaxoSmithKline
- MYR
- Tekmira
- Merck
Ask authors/readers for more resources
Liver biopsies are traditionally performed to determine the cause and stage of liver disease, as well as to inform treatment decisions and determine prognosis. In 2001, Bravo et al. observed that liver biopsy is usually the most specific test to assess the nature and severity of liver diseases. During the past 16 years, however, the clinical use of liver biopsies has undergone a profound transformation. Validated alternatives to liver biopsy have proliferated, spurred by concerns about the costs of biopsy and the risk of complications. Furthermore, research has brought a new understanding of the limitations of liver biopsy. In this review, we discuss the role of liver biopsy in the current era, as well as the accuracy of noninvasive evaluations and their use in clinical practice for determining the cause of liver disease and focal liver lesions and for detecting advanced fibrosis and cirrhosis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available